Oryzon Genomics SA (ORY) — Cash Flow-to-Debt Ratio
Oryzon Genomics SA (ORY) has a Cash Flow-to-Debt Ratio of -0.09x as of June 2023, meaning its operating cash flow of €-2.41 Million could theoretically repay 0% of its total liabilities (€26.10 Million) in one year. See ORY financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Oryzon Genomics SA Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Oryzon Genomics SA across 13 annual periods. For the full cash flow conversion analysis, see Oryzon Genomics SA operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Oryzon Genomics SA (2013–2025)
Year-by-year debt coverage analysis for Oryzon Genomics SA. Check ORY cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.09x | €-2.36 Million | €26.68 Million | ▲ +66.4% |
| 2024 | -0.26x | €-5.69 Million | €21.67 Million | ▼ -1047.2% |
| 2023 | -0.02x | €-574.96K | €25.13 Million | ▲ +61.4% |
| 2022 | -0.06x | €-1.85 Million | €31.13 Million | ▲ +60.5% |
| 2021 | -0.15x | €-3.63 Million | €24.12 Million | ▲ +43.3% |
| 2020 | -0.27x | €-4.82 Million | €18.18 Million | ▲ +99.5% |
| 2019 | -49.56x | €-3.93 Million | €79.38K | ▼ -166006.5% |
| 2018 | -0.03x | €-666.09K | €22.33 Million | ▲ +83.1% |
| 2017 | -0.18x | €-4.71 Million | €26.61 Million | ▲ +4.6% |
| 2016 | -0.19x | €-5.01 Million | €27.02 Million | ▼ -565.5% |
| 2015 | 0.04x | €523.14K | €13.14 Million | ▼ -96.0% |
| 2014 | 1.00x | €12.13 Million | €12.16 Million | ▲ +15.4% |
| 2013 | 0.86x | €12.13 Million | €14.04 Million | — |